Hospira CEO on Personal Involvement
This article was originally published in RPM Report
Executive Summary
One of the foundations for resolving repeat QC problems is convincing FDA that compliance is the top priority of senior management. When FDA officials cannot reach senior management or sense a lack of commitment at the top, the assumption is that the culture and organizational structure of the firm
You may also be interested in...
Hospira on the Ball: Paying Attention to FDA Complaints Under New CEO
Hospira’s new CEO Mike Ball was charting a global expansion and touting a move into biosimilars. Then the lingering quality control discussions with FDA caught up with the company and forced their way to the top of his agenda. That may be an important step for the company in the long-term.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.